Condition: Breast Cancer · Triple Negative Breast Cancer · PD-L1 Negative · Sponsor: Dana-Farber Cancer Institute
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * Sacituzumab govitecan (Trodelvy™;IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)
This description comes directly from the study's public registry record.
Ana C Garrido-Castro, MD · 617-632-6409 · Ana_Garrido-Castro@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Stamford Hospital | Stamford, Connecticut, United States | Recruiting |
| Miami Cancer Institute at Baptist Health (Kendall) | Miami, Florida, United States | Recruiting |
| Miami Cancer Institute at Baptist Health | Plantation, Florida, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| Eastern Maine Medical Center | Brewer, Maine, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| DFCI @ Foxborough | Foxborough, Massachusetts, United States | Recruiting |
| DFCI @ Milford Regional Hospital | Milford, Massachusetts, United States | Recruiting |
| DF/BWCC in Clinical Affiliation with South Shore Hospital | South Weymouth, Massachusetts, United States | Recruiting |
| The University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| The Christ Hospital Cancer Center | Cincinnati, Ohio, United States | Recruiting |
| Ohio State University Medical Center | Columbus, Ohio, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04468061